Physician profile
Sheela Vardey
NPI 1407048978
$2,620.86
in general payments reported to CMS, 2019-2025
29 companies · $555 in 2025
The $555 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $25.29 · 2021: $11.97 · 2022: $186 · 2023: $685 · 2024: $895 · 2025: $555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,134.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $1,065.28 | 2022-2025 | Azstarys |
| Novo Nordisk INC | $421.70 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Lilly USA, LLC | $117.92 | 2022-2025 | Mounjaro, Trulicity, Zepbound |
| Sanofi-Aventis U.S. LLC | $117.32 | 2025 | |
| Pfizer INC. | $113.27 | 2019-2025 | |
| Sobi, INC | $100.00 | 2019 | |
| Supernus Pharmaceuticals, INC. | $98.20 | 2022-2023 | Qelbree |
| Xeris Pharmaceuticals, INC. | $72.92 | 2023 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.46 | 2019-2024 | Jardiance |
| Dexcom, INC. | $48.72 | 2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $48.43 | 2022-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Merck Sharp & Dohme LLC | $36.52 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $29.25 | 2025 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $27.51 | 2022 | |
| Mylan Specialty L.P. | $27.38 | 2024 | Yupelri |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.44 | 2025 | |
| Janssen Pharmaceuticals, INC | $22.63 | 2024 | Spravato |
| Abbvie INC. | $21.87 | 2025 | |
| Ironshore Pharmaceuticals INC. | $21.07 | 2022 | |
| Alk-Abello, INC | $20.64 | 2024 | Grastek, Ragwitek, Odactra |
| Astrazeneca Pharmaceuticals LP | $20.20 | 2024 | Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.78 | 2019 | |
| Collegium Pharmaceutical, INC. | $15.81 | 2025 | Jornay Pm |
| Abbott Laboratories | $14.93 | 2025 | Freestyle Libre 3 |
| Sanofi Pasteur INC. | $14.08 | 2025 | |
| Genentech USA, INC. | $13.12 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.32 | 2019 | |
| Tris Pharma INC | $11.62 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheela Vardey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.